Literature DB >> 6372322

Hemolytic Escherichia coli strains in the human fecal flora as potential urinary pathogens.

J Hacker, G Schröter, A Schrettenbrunner, C Hughes, W Goebel.   

Abstract

Hemolysin production is presumed to be a virulence factor in extraintestinal, e.g. urinary tract, infections caused by Escherichia coli. In order to investigate its incidence among the fecal flora, particularly in combination with other presumptive virulence factors, 369 and 373 fecal isolates from Würzburg, FRG and Lima, Peru respectively were examined. 12% of the former and 4% of the latter were hemolytic (Hly+) compared to 33% of 249 E. coli strains isolated from urinary tract infections in Würzburg. In comparison to those which were non hemolytic (Hly-), Hly+ fecal E. coli isolates were associated to a far greater extent with other factors implicated in urinary tract virulence. 41% of these Hly+ strains (cf. 8% Hly-) possessed mannose resistant hemagglutination (MRHA types V, VI, VII). In addition they belonged to the "common O serogroups" O1, O2, O4, O6, O7, O8, O18, O25, O75 in 61% of cases (cf. 25% Hly-) and they possessed K5 antigen in 13% of instances (cf. 2.5% Hly-). The occurrence of these three virulence factors among Hly+ fecal E. coli strains is very similar to that observed among E. coli urinary isolates. One may conclude that these Hly+ fecal strains constitute a "pool" of potential urinary tract pathogens.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6372322

Source DB:  PubMed          Journal:  Zentralbl Bakteriol Mikrobiol Hyg A        ISSN: 0174-3031


  23 in total

1.  Enterohemolysin production is associated with a temperate bacteriophage in Escherichia coli serogroup O26 strains.

Authors:  L Beutin; L Bode; M Ozel; R Stephan
Journal:  J Bacteriol       Date:  1990-11       Impact factor: 3.490

2.  Virulence patterns and long-range genetic mapping of extraintestinal Escherichia coli K1, K5, and K100 isolates: use of pulsed-field gel electrophoresis.

Authors:  M Ott; L Bender; G Blum; M Schmittroth; M Achtman; H Tschäpe; J Hacker
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

3.  Characterization of monoclonal antibodies against alpha-hemolysin of Escherichia coli.

Authors:  R L Oropeza-Wekerle; P Kern; D Sun; S Muller; J P Briand; W Goebel
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

Review 4.  The different hemolysins of Escherichia coli.

Authors:  L Beutin
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

Review 5.  Escherichia coli in extra-intestinal infections.

Authors:  I Orskov; F Orskov
Journal:  J Hyg (Lond)       Date:  1985-12

6.  Beta-lactamase types and beta-lactam resistance of Escherichia coli strains with chromosomally mediated ampicillin resistance.

Authors:  R Marre; S Aleksic
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

7.  Correlation between esterase electrophoretic polymorphism and virulence-associated traits in extra-intestinal invasive strains of Escherichia coli.

Authors:  P Goullet; B Picard; M Contrepois; J De Rycke; J Barnouin
Journal:  Epidemiol Infect       Date:  1994-02       Impact factor: 2.451

8.  Role of cell-bound hemolysin as a pathogenicity factor for Serratia infections.

Authors:  W König; Y Faltin; J Scheffer; H Schöffler; V Braun
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

9.  Induction of histamine release from rat mast cells and human basophilic granulocytes by clinical Escherichia coli isolates and relation to hemolysin production and adhesin expression.

Authors:  W Gross-Weege; W König; J Scheffer; W Nimmich
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

10.  Association of enterohemorrhagic Escherichia coli hemolysin with serotypes of shiga-like-toxin-producing Escherichia coli of human and bovine origins.

Authors:  C Gyles; R Johnson; A Gao; K Ziebell; D Pierard; S Aleksic; P Boerlin
Journal:  Appl Environ Microbiol       Date:  1998-11       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.